Contact
searchSearch
HMP Global
Login
Quiz: Which SOC Treatment is an Alternative for Imatinib Intolerant Advanced, mGIST?
11/16/2021
Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.
Approved globally, _______ is established as the standard-of-care second line for the treatment of advanced and/or metastatic gastrointestinal stromal tumor patients after failure or intolerance to imatinib.
Approved globally, _______ is...
11/16/2021
Oncology
Sunitinib Displays Safety, Efficacy for Imatinib-Resitant Patients with Advanced GIST
11/15/2021
A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.
A real-world study confirms sunitinib is found as a safe and effective option for the treatment of imatinib-resistant, advanced GIST patients.
A real-world study confirms...
11/15/2021
Oncology
Imatinib Exhibits Viability as Neoadjuvant Therapy for GIST
11/15/2021
Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.
Imatinib is found feasible as neoadjuvant therapy for GIST, with the potential of to tumor size reduction and high morbidity prevention, according to data presented at the 2021 CTOS Annual Meeting.
Imatinib is found feasible as...
11/15/2021
Oncology
Conference Coverage
Dose Escalation of Ripretinib Yields OR in Tumor Progressive GIST
11/15/2021
Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.
Investigators sought to evaluate the tolerability and response of patients with GIST treated outside clinical trials with ripretinib dose escalation, presented at the 2021 CTOS Annual Meeting.
Investigators sought to evaluate...
11/15/2021
Oncology

Experts who specialize in sarcomas come together to discuss new developments, treatments, and advancements in the field.

Tracks

GIST

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use